Pharmaron Beijing Co

Pharmaron Beijing Co Net Margin

The Net Profit Margin of Pharmaron Beijing Co (300759.SZ) as of Nov 11, 2026 is 11.80 %. In the previous year, Net Profit Margin was 14.61 % — a change of -19.19% (lower).

Net Margin

11.80 %

YoY

-19.19%

Last updated:

Net Profit Margin of Pharmaron Beijing Co is 2025 11.80 % . Net Profit Margin of Pharmaron Beijing Co was 2024 14.61 % . It decreases by -19.19% lower compared to the previous year.

For Pharmaron Beijing Co, the net margin of 11.8% is down versus 22.3% a few years ago.

The Pharmaron Beijing Co Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
11.45 CNY
Jan 1, 2019
14.56 CNY
Jan 1, 2020
22.84 CNY
Jan 1, 2021
22.31 CNY
Jan 1, 2022
13.39 CNY
Jan 1, 2023
13.88 CNY
Jan 1, 2024
14.61 CNY
Jan 1, 2025
11.80 CNY
The Pharmaron Beijing Co Net Margin history
YEARNet MarginYoY
11.80 %-19.19%
14.61 %+5.28%
13.88 %+3.64%
13.39 %-40.00%
22.31 %-2.29%
22.84 %+56.81%
14.56 %+27.17%
11.45 %+13.81%
10.06 %-7.04%
10.83 %+65.36%
6.55 %+146.46%
2.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pharmaron Beijing Co Stock analysis

What does Pharmaron Beijing Co do? Pharmaron Beijing Co Ltd generates revenue through four business segments. The Laboratory Services segment offers laboratory chemistry, drug metabolism, pharmacokinetics, absorption, distribution, metabolism, and excretion testing, biology, safety assessment, and discovery of biological agents. The CMC Service segment provides process development, preform production, and analysis for drug manufacturing. The Clinical Development Service segment delivers clinical research, on-site management organization, regulatory biological analysis, and radioactive labeling scientific services. The Biologics and CGT Services segment focuses on macromolecular drug discovery, development, and production, alongside cell gene therapy method development. These services are primarily purchased by pharmaceutical companies and biotechnology firms engaged in drug discovery and development processes. Pharmaron Beijing Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharmaron Beijing Co stock

Net Profit Margin of Pharmaron Beijing Co is 11.80 % in 2025.

Net Profit Margin of Pharmaron Beijing Co changed from 14.61 % to 11.80 %, representing a -19.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Pharmaron Beijing Co since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Pharmaron Beijing Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Pharmaron Beijing Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Pharmaron Beijing Co